Preparation method of pretreated and activated mesenchymal stem cells and application thereof in myeloid leukemia treatment

The invention belongs to the technical field of medical biology, and particularly relates to an application of umbilical cord derived mesenchymal stem cells to acute and chronic myelogenous leukemia differentiation therapy. The mesenchymal stem cells provided by the invention are mesenchymal stem cells (Active MSCs) obtained by pretreating and activating human source umbilical cord mesenchymal stem cells (UC-MSCs) by using specific chemical micromolecules-1,25D3 (1,2-dihydroxy vitamin D3, 1,25-Dihydoxyvitamine D3). The Active MSCs can efficiently induce AML cell differentiation, and the capacity is achieved by secreting interleukin 6 (IL-6) and indole-2,3-dioxygenase (IDO). The mesenchymal stem cells are allogeneic mesenchymal stem cells, the expression and secretion capacity of IL-6 and IDO of the mesenchymal stem cells can be remarkably improved by at least three times after the mesenchymal stem cells are treated and activated by the VDR agonists 1, 25D3, and the anti-AML capacity isremarkably enhanced. Com